Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

{
  "signal_id": "36f40be9-86ce-708b-99ee-c7bb0e26755a",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-01T05:00:00+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/01/3372510/0/en/regeneron-and-sanofi-expand-global-alliance-with-multiple-next-generation-long-acting-immunology-antibodies.html",
    "title": "Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies",
    "excerpt": "REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Regeneron and Sanofi to host a conference call for investors and analysts today at 8:00 am ET/2:00 pm CET TARRYTOWN, N.Y. and PARIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-acting antibodies to the alliance that has jointly established Dupixent ® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies’ more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world. “The Regeneron-Sanofi alliance has been one of the most productive in biopharma history. This agreement builds on that foundation to bring the next generation of immunology medicines to patients...",
    "product": "REGN20423",
    "summary": "Regeneron is developing REGN20423, a long-acting IL-13 monoclonal antibody currently in a Phase 1 clinical trial for atopic dermatitis, as part of its expanded collaboration with Sanofi.",
    "planning": true,
    "image_url": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1",
    "confidence": 0.9,
    "product_data": {
      "name": "REGN20423",
      "full_text": "IL-13 antibody REGN20423",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-10-01T05:00:00Z",
    "article_sentence": "IL-13 antibody REGN20423 is currently in a Phase 1 clinical trial for atopic dermatitis, and the other three antibodies are expected to enter clinical studies in 2027.",
    "related_company_name": "Sanofi",
    "related_company_domain": "sanofi.com"
  }
}

curl https://signals.autobound.ai/v1/signals/36f40be9-86ce-708b-99ee-c7bb0e26755a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'